This study is testing a drug called NEO100 (a purified form of perillyl alcohol) for people with high-grade meningioma (a type of brain tumor) that has returned, grown, or wasn't fully removed by surgery. You could join if you have a Grade II or III meningioma that has come back, progressed, or is still present after surgery and radiation. The study aims to see how safe and effective NEO100 is, and how your body processes it. Success in this study will be measured by how many participants are still alive and without their cancer progressing after six months. Up to 30 patients will be included in this study.

Study design

This is an open-label, multi-site Phase 2 study, meaning both you and your doctors will know you are receiving NEO100. The study plans to enroll up to 30 participants.

What's involved

You would self-administer NEO100 four times daily on a 28-day cycle. This treatment would continue until your disease progresses, you pass away, or you choose to leave the study.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, progression-free survival, is measured at six months. The total duration of follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.